Significant and clinically meaningful reductions in pain scores in small fiber neuropathy and a breakthrough designation for Vertex Pharmaceuticals Inc.’s VX-150 look set to put the product on a fast path towards the regulators.
Vertex Pain Product VX-150 Comes Out Of The Shadows
Solid Phase II efficacy data for Vertex’s pain product have brought it blinking into the light. Analysts are hoping it will lead to an additional revenue stream for Vertex behind its all-conquering cystic fibrosis franchise.
